Literature DB >> 2452179

Synergistic cytotoxicity of recombinant human TNF and various anti-cancer drugs.

N Watanabe1, Y Niitsu, N Yamauchi, Y Ohtsuka, H Sone, H Neda, M Maeda, I Urushizaki.   

Abstract

A synergistic increase in the cytotoxic effects of recombinant human tumor necrosis factor (rH-TNF) and anti-cancer drugs was demonstrated in vitro. The cytotoxicity of rH-TNF against L-M cells in combination with Mitomycin C (MMC), Adriamycin (ADM), Cytosine arabinoside (Ara-C), Actinomycin D (ACD), Daunomycin (DM), Cisplatin (CDDP), Vincristine (VCR), and 5-Fluorouracil (5FU), based on the concentration necessary for 50% inhibition of cell growth (IC50), was 4 to 347 times as high as that of rH-TNF alone. The results suggest that combination therapy including rH-TNF and anti-cancer drugs may be of value in the treatment of malignancy in human patients.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2452179     DOI： 10.3109/08923978809014406

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN： 0892-3973            Impact factor:   2.730


  8 in total

1.  Synergistic cytotoxicity of human recombinant tumour necrosis factor alpha combined with microtubule effectors.

Authors:  J Baumgart; B Schlott; J Suehnel; W Vater; W Schulze; D Behnke
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  Synergistic enhancement by interleukin-1 alpha of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice.

Authors:  C S Johnson; M J Chang; W D Yu; R A Modzelewski; J R Grandis; D R Vlock; P Furmanski
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Phase 2 trial of recombinant tumor necrosis factor-alpha in combination with dactinomycin in children with recurrent Wilms tumor.

Authors:  Holly J Meany; Nita L Seibel; Junfeng Sun; Jerry Z Finklestein; Judith Sato; John Kelleher; Paul Sondel; Gregory Reaman
Journal:  J Immunother       Date:  2008-09       Impact factor: 4.456

Review 4.  Targeting apoptosis in cancer therapy.

Authors:  Benedito A Carneiro; Wafik S El-Deiry
Journal:  Nat Rev Clin Oncol       Date:  2020-03-23       Impact factor: 66.675

5.  Growth-inhibiting effect of intratumoral recombinant human tumor necrosis factor on an experimental model of primitive neuroectodermal tumor.

Authors:  J Vaquero; M Zurita; S Oya
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

6.  Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.

Authors:  P Osterlund; A Orpana; I Elomaa; H Repo; H Joensuu
Journal:  Br J Cancer       Date:  2002-09-09       Impact factor: 7.640

7.  Reversal of tumor necrosis factor resistance in tumor cells by adriamycin via suppression of intracellular resistance factors.

Authors:  N Watanabe; T Okamoto; N Tsuji; H Sasaki; S Akiyama; D Kobayashi; T Sato; N Yamauchi; Y Niitsu
Journal:  Jpn J Cancer Res       Date:  1995-04

8.  Dipyridamole combined with tumor necrosis factor-alpha enhances inhibition of proliferation in human tumor cell lines.

Authors:  N Suzuki; S Sekiya; I Sugano; T Kojima; H Yamamori; Y Takakubo
Journal:  Jpn J Cancer Res       Date:  1995-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.